Korde, Neha

Publications

Sort by

Co-Author Network

selected publications

Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 Academic Article GET IT
Times cited: 29
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 5
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia & lymphoma. 2018 Letter GET IT
Times cited: 14
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer chemotherapy and pharmacology. 2017 Academic Article GET IT
Times cited: 1
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 2
Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia & lymphoma. 2016 Letter GET IT
Times cited: 6
Treatment of high-risk smoldering myeloma. 2016 GET IT
Times cited: 2
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 8
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 9
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 114
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 20
Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics. Current hematologic malignancy reports. 2016 Review GET IT
Times cited: 7
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016 Letter GET IT
Times cited: 12
Monoclonal gammopathy-associated pure red cell aplasia. British journal of haematology. 2016 Academic Article GET IT
Times cited: 15
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone marrow transplantation. 2016 Academic Article GET IT
Times cited: 34
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 34
Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. The Journal of molecular diagnostics : JMD. 2015 Academic Article GET IT
Times cited: 34
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. eLife. 2015 Academic Article GET IT
Times cited: 59
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA oncology. 2015 Academic Article GET IT
Times cited: 238
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. JAMA oncology. 2015 Academic Article GET IT
Times cited: 80
Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 88
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica. 2014 Editorial Article GET IT
Times cited: 3
Dilemmas in treating smoldering multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Review GET IT
Times cited: 19
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 20
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. Clinical advances in hematology & oncology : H&O. 2014 Review GET IT
Times cited: 10
The road to treating smoldering multiple myeloma. Clinical lymphoma, myeloma & leukemia. 2014 Review GET IT
Times cited: 3
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine. 2014 Academic Article GET IT
Times cited: 15
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. 2014 Letter GET IT
Times cited: 104
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leukemia & lymphoma. 2014 Review GET IT
Times cited: 25
Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014 Review GET IT
Times cited: 45
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014 Academic Article GET IT
Times cited: 112
Minimal residual disease: what are the minimum requirements?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Letter GET IT
Times cited: 17
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia research. 2013 Academic Article GET IT
Times cited: 66
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leukemia & lymphoma. 2013 Letter GET IT
Times cited: 11
Smoldering multiple myeloma: present position and potential promises. European journal of haematology. 2013 Review GET IT
Times cited: 5
Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia. 2013 Letter GET IT
Times cited: 21
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 75
MGUS prevalence in a cohort of AML patients. Blood. 2013 Letter GET IT
Times cited: 3
Pursuing the curative blueprint for early myeloma. Blood. 2013 Academic Article GET IT
Times cited: 15
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. American journal of hematology. 2012 Academic Article GET IT
Times cited: 8
Evolving therapeutic paradigms for multiple myeloma: back to the future. Leukemia & lymphoma. 2012 Review GET IT
Times cited: 13
Treating myeloma: the future is already here!. Blood. 2012 Comment GET IT
Times cited: 6
Bortezomib to treat the TEMPI syndrome. The New England journal of medicine. 2012 Letter GET IT
Times cited: 35
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012 Review GET IT
Times cited: 91
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leukemia & lymphoma. 2011 Letter GET IT
Times cited: 8
Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia. 2011 Letter GET IT
Times cited: 13
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011 Academic Article GET IT
Times cited: 152
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert review of molecular diagnostics. 2011 Review GET IT
Times cited: 27
Current and future imaging modalities for multiple myeloma and its precursor states. Leukemia & lymphoma. 2011 Review GET IT
Times cited: 25
Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities. Oncology (Williston Park, N.Y.). 2011 Comment GET IT
Times cited: 10
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 2011 Review GET IT
Times cited: 143
Myelomagenesis: capturing early microenvironment changes. Seminars in hematology. 2011 Review GET IT
Times cited: 9

more ...

less ...

Background

education and training

M.D., Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey 2005
B.S., Lehigh University 2000

Contact

full name

Neha Korde

VIVO Weill Cornell Medical College

Neha Korde Assistant Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name